Companies: 10,795·Total market cap: $144.5T
Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc.

ARPONASDAQHealthcare
$2.20
$-0.02(-0.90%)
Market Cap$53669220
P/E Ratio
52W High$2.3
52W Low$2.16

Aerpio Pharmaceuticals, Inc.(ARPO)股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

arpo · 股价预测 · 4 位分析师(近3月)· FMP · 更新于 2021年7月8日

分析师评级与共识

基于过去 3 个月内 4 位华尔街分析师

SellBuy

Buy

4 位分析师

共识

评级分布

Strong Buy
0
Buy
2
Hold
2
Sell
0
Strong Sell
0
合计: 4 · 买入占比: 50.0%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $2.20

Aerpio Pharmaceuticals, Inc.(ARPO)的分析师共识为 Buy,基于过去 3 个月内 4 位华尔街分析师的评级。ARPO 的 12 个月平均目标价为 $0.00,相对当前价 $2.20 代表 +0.0% 的潜在上行空间。

短期股价预测

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-10$2.262.69%

1-day model range: $2.24–$2.28. Peak: $2.28 (+2.69%).

长期股价预测

⚠️ 在满 252 个交易日历史(IPO/上市时间较短)前不展示长期预测;短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号(SMA×6 + EMA×6 + RSI + MACD)· EEAT 方法论透明

Market Sentiment

NEUTRAL

Based on 14 technical indicators

36%50%14%
5Buy
7Neutral
2Sell
RSI (14)56.5Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · ARPO · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$2.20SELL
MA 10$2.19BUY
MA 20$2.12BUY
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $ARPO · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$2.20SELL
EMA 10$2.18BUY
EMA 20$2.16BUY
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $ARPO · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
HC Wainwright & Co.2021-07-08
Upgrade ↑
NeutralBuy
HC Wainwright & Co.2020-12-14
Maintains
NeutralNeutral
HC Wainwright & Co.2020-08-13
Maintains
NeutralNeutral
HC Wainwright & Co.2020-06-25
Maintains
NeutralNeutral
H.C. Wainwright2019-06-12
Maintains
NeutralNeutral
Guggenheim2019-03-19
Downgrade ↓
BuyNeutral
H.C. Wainwright2019-03-19
Downgrade ↓
BuyNeutral
Cantor Fitzgerald2019-01-18
Maintains
OverweightOverweight
Guggenheim2018-09-19
Maintains
BuyBuy
H.C. Wainwright2018-04-18
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Aerpio Pharmaceuticals, Inc. (ARPO) stock. Of the recent 10 rating actions, 1 were upgrades and 2 were downgrades. 4 analysts currently cover ARPO.

分析师推荐趋势

Buy ratings01↑ +1
Hold ratings202
Sell ratings00

ARPO analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.

财务预测:EPS 与营收一致预期

Revenue This Year

Revenue Next Year

EPS This Year

EPS Next Year

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ARPO EPS of $ for the current fiscal year, based on estimates from 0 analysts. The ARPO revenue forecast is for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

ARPO 股价预测由两类独立数据源支撑:来自 4 位华尔街分析师(S&P Global / FMP)的共识评级,以及基于历史日终价计算的技术分析。ARPO 的共识目标价为 $0.00(+0.0% 上行空间),分析师共识为 Buy。

ARPO 的短期预测(明日)为 $2.26(+2.69%)。

Aerpio Pharmaceuticals, Inc. 在 NASDAQ 上市,代码 ARPO。ARPO 在 2027 年的整体展望偏积极,在覆盖分析师中约 50% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

ARPO 预测 · 8 个问题

根据 4 位华尔街分析师,ARPO 的 12 个月平均目标价为 $0.00,最高 $0.00、最低 $0.00。若有图表,中位目标价可在上方查看。相对当前价 $2.20,隐含约 +0.0% 的上行空间。

ARPO 目标价ARPO 分析师目标价ARPO 12个月目标价目标价 ARPO

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.